Stanford Cancer Institute shared a post on LinkedIn:
“We’re excited to announce that Vivek Subbiah, MD, has been appointed the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. He will lead our Early Drug Development Program to expand access to innovative treatments for Stanford cancer patients, with a focus on phase 1 clinical trials, biomarker-driven study design, targeted therapeutics, and rare cancers.
Dr. Subbiah will also join Stanford Health Care as the executive medical director for cancer novel therapies and clinical trial network development, where he will provide strategic leadership to grow clinical trial infrastructure, accelerate evaluation of cutting-edge treatments, and strengthen regional and national research partnerships. Additionally, he will assume a professorship in the Stanford Department of Medicine Division of Oncology.
An internationally recognized leader in tumor-agnostic precision oncology, Dr. Subbiah has served as the principal investigator in over 150 phase 1/2 trials, co-investigator in over 250 clinical trials, and author on over 450 peer-reviewed publications. He has led and contributed to the clinical development of multiple first-in-human treatments, several of which resulted in regulatory approvals and changes to clinical practice.
He joins Stanford after serving as chief of early-phase drug development at Sarah Cannon Research Institute, where he oversaw nine drug development units implementing first-in-human clinical trials and led the expansion of early-phase capabilities across a network of more than 1,300 physicians at over 250 locations in 24 states. Previously, he held leadership roles at MD Anderson Cancer Center as the executive director of medical oncology research and the clinical medical director in the Division of Cancer Medicine.
Recognized as one of the Top 100 Most Influential People in Oncology in 2025, Dr. Subbiah’s appointment signifies an important opportunity to further advance Stanford’s national leadership in early drug development and precision oncology, enhance patient access to transformative therapies, and strengthen the integration of discovery, translational research, and patient-centered care.”
Other articles featuring Stanford Cancer Institute on OncoDaily.